Skip to main content
SpringerLink
Log in
Book cover

Urologic Oncology pp 1–26Cite as

Metastatic Surgery in Advanced Renal Cell Carcinoma

  • Living reference work entry
  • First Online:

  • 275 Accesses

Abstract

Management of patients with advanced and metastatic renal cell carcinoma is a challenging task, which often demands a multidisciplinary approach. In the cytokine immunotherapy era, cytoreductive nephrectomy in combination with immunotherapy was shown to be superior to immunotherapy alone, thus making cytoreductive nephrectomy a cornerstone of treatment. In the more recent era of targeted molecular therapies, cytoreductive nephrectomy seems to still retain its role in management of these patients despite lack of level 1 evidence so far. However, proper patient selection has been shown to be of utmost importance to assure benefit from this surgical endeavor. Prospective trials aiming to inform the field regarding efficacy as well as timing of cytoreductive nephrectomy in the targeted therapy era are underway and eagerly awaited, despite encountering challenges during study enrollment. Additionally, the recent introduction of checkpoint inhibitors once again targeting the immune axis is changing treatment landscape and challenging the benefit of cytoreductive nephrectomy. Metastasectomy on the other hand is currently being utilized for patients with relatively indolent oligometastatic disease. Despite lack of level 1 evidence, available evidence supports long-term remission with metastasectomy for some patients. This chapter aims to summarize the currently available evidence for cytoreductive nephrectomy as well as metastasectomy and give an outlook into the future with regard to new developments in this arena.

This is a preview of subscription content, log in via an institution.

References

  • Abel EJ, Culp SH, et al. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol. 2011;60(6):1273–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Abern MR, Scosyrev E, et al. Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. Anticancer Res. 2014;34(5):2405–11.

    PubMed  Google Scholar 

  • Aizer AA, Urun Y, et al. Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC). BJU Int. 2014;113(5b):E67–74.

    Article  PubMed  PubMed Central  Google Scholar 

  • Alt AL, Boorjian SA, et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011;117(13):2873–82.

    Article  PubMed  Google Scholar 

  • Altoos B, Amini A, et al. Local control rates of metastatic renal cell carcinoma (RCC) to thoracic, abdominal, and soft tissue lesions using stereotactic body radiotherapy (SBRT). Radiat Oncol. 2015;10:218.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Alva A, Daniels GA, et al. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother. 2016;65(12):1533–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Amendola BE, Wolf AL, et al. Brain metastases in renal cell carcinoma: management with gamma knife radiosurgery. Cancer J. 2000;6(6):372–6.

    CAS  PubMed  Google Scholar 

  • Amini A, Altoos B, et al. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: is RCC truly radioresistant? Pract Radiat Oncol. 2015;5(6):e589–96.

    Article  PubMed  PubMed Central  Google Scholar 

  • Andrews DW, Scott CB, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665–72.

    Article  PubMed  Google Scholar 

  • Antonelli A, Arrighi N, et al. Surgical treatment of atypical metastasis from renal cell carcinoma (RCC). BJU Int. 2012;110(11 Pt B):E559–63.

    Article  PubMed  Google Scholar 

  • Aoyama H, Shirato H, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295(21):2483–91.

    Article  CAS  PubMed  Google Scholar 

  • Assouad J, Petkova B, et al. Renal cell carcinoma lung metastases surgery: pathologic findings and prognostic factors. Ann Thorac Surg. 2007;84(4):1114–20.

    Article  PubMed  Google Scholar 

  • Bamias A, Tzannis K, et al. Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study. Clin Genitourin Cancer. 2014;12(5):373–83.

    Article  PubMed  Google Scholar 

  • Barbastefano J, Garcia JA, et al. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int. 2010;106(9):1266–9.

    Article  CAS  PubMed  Google Scholar 

  • Barney JD, Churchill EJ. Adenocarcinoma of the kidney with metastasis to the lung cured by nephrectomy and lobectomy. J Urol. 1939;42:269.

    Article  Google Scholar 

  • Barnholtz-Sloan JS, Sloan AE, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865–72.

    Article  PubMed  Google Scholar 

  • Bex A, Horenblas S, et al. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur Urol. 2002;42(6):570–4. discussion 575–6

    Article  CAS  PubMed  Google Scholar 

  • Bex A, de Bruijn R, et al. Time to targeted therapy after cytoreductive nephrectomy (CN) and surveillance in patients with synchronous unresectable metastases of renal cell carcinoma (RCC). J Clin Oncol. 2016a;34(2 suppl):604.

    Article  Google Scholar 

  • Bex A, Ljungberg B, et al. The role of cytoreductive nephrectomy: European Association of Urology recommendations in 2016. Eur Urol. 2016b;70(6):901–5.

    Article  PubMed  Google Scholar 

  • Bianchi M, Sun M, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol. 2012;23(4):973–80.

    Article  CAS  PubMed  Google Scholar 

  • Borregales LD, Adibi M, et al. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Ther Adv Urol. 2016;8(2):130–41.

    Article  CAS  PubMed  Google Scholar 

  • Bruno JJ 2nd, Snyder ME, et al. Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival. BJU Int. 2006;97(5):933–8.

    Article  PubMed  Google Scholar 

  • Carden CP, Larkin JM, et al. What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol. 2008;10(4):624–30.

    Article  PubMed  PubMed Central  Google Scholar 

  • Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376(4):354–66.

    Article  CAS  PubMed  Google Scholar 

  • Choueiri TK, Xie W, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011;185(1):60–6.

    Article  PubMed  Google Scholar 

  • ClinicalTrials.gov. Nivolumab and stereotactic ablative radiation therapy (SAbR) for metastatic clear cell renal cell carcinoma. In: Health USNIo, editor. www.clinicaltrials.gov; 2016.

  • ClinicalTrials.gov. Nivolumab vs nivolumab + bevacizumab vs nivolumab + ipilimumab in metastatic renal cell carcinoma (mRCC) (NCT02210117). 2017a. https://clinicaltrials.gov/ct2/show/NCT02210117?term=cytoreductive+nephrectomy&rank=3. Accessed 3 Feb 2017.

  • ClinicalTrials.gov. Pazopanib hydrochloride in treating patients with metastatic kidney cancer who have no evidence of disease after surgery. In: Health USNIo, editor. 2017b.

    Google Scholar 

  • Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353(23):2477–90.

    Article  CAS  PubMed  Google Scholar 

  • Conti SL, Thomas IC, et al. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer. 2014;134(9):2245–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cost NG, Delacroix SE Jr, et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol. 2011;59(6):912–8.

    Article  CAS  PubMed  Google Scholar 

  • Culine S, Bekradda M, et al. Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer. 1998;83(12):2548–53.

    Article  CAS  PubMed  Google Scholar 

  • Culp SH, Tannir NM, et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010;116(14):3378–88.

    Article  PubMed  Google Scholar 

  • Dabestani S, Marconi L, et al. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol. 2014;15(12):e549–61.

    Article  PubMed  Google Scholar 

  • De Meerleer G, Khoo V, et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol. 2014;15(4):e170–7.

    Article  PubMed  Google Scholar 

  • Dekernion JB, Ramming KP, et al. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol. 1978;120(2):148–52.

    Article  CAS  PubMed  Google Scholar 

  • Dengina N, Tsimafeyeu I, et al. Current role of radiotherapy for renal-cell carcinoma: review. Clin Genitourin Cancer. 2016 Sep;15(2):183–7.

    Article  PubMed  Google Scholar 

  • Ebele JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organisation classification of tumours. Lyon: International Agency for Research on Cancer; 2004.

    Google Scholar 

  • Eggener SE, Yossepowitch O, et al. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol. 2008;180(3):873–8. discussion 878

    Article  PubMed  PubMed Central  Google Scholar 

  • Escudier B, Eisen T, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.

    Article  CAS  PubMed  Google Scholar 

  • Esrig D, Ahlering TE, et al. Experience with fossa recurrence of renal cell carcinoma. J Urol. 1992;147(6):1491–4.

    Article  CAS  PubMed  Google Scholar 

  • Evenski A, Ramasunder S, et al. Treatment and survival of osseous renal cell carcinoma metastases. J Surg Oncol. 2012;106(7):850–5.

    Article  PubMed  Google Scholar 

  • Fallick ML, McDermott DF, et al. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol. 1997;158(5):1691–5.

    Article  CAS  PubMed  Google Scholar 

  • Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon: International Agency for Research on Cancer; 2014.

    Google Scholar 

  • Flanigan RC, Salmon SE, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–9.

    Article  CAS  PubMed  Google Scholar 

  • Flanigan RC, Mickisch G, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171(3):1071–6.

    Article  PubMed  Google Scholar 

  • Fokas E, Henzel M, et al. Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery?: analysis of 88 patients. Strahlenther Onkol. 2010;186(4):210–7.

    Article  PubMed  Google Scholar 

  • Fuchs B, Trousdale RT, et al. Solitary bony metastasis from renal cell carcinoma: significance of surgical treatment. Clin Orthop Relat Res. 2005;(431):187–92.

    Google Scholar 

  • Fyfe G, Fisher RI, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688–96.

    Article  CAS  PubMed  Google Scholar 

  • Gershman B, Moreira DM, et al. Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy. Eur Urol. 2016;69(1):84–91.

    Article  PubMed  Google Scholar 

  • Gershman B, Thompson RH, et al. Lymph node dissection is not associated with improved survival among patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma: a propensity score based analysis. J Urol. 2017;197(3 Pt 1):574–9.

    Article  PubMed  Google Scholar 

  • Ghavamian R, Klein KA, et al. Renal cell carcinoma metastatic to the pancreas: clinical and radiological features. Mayo Clin Proc. 2000;75(6):581–5.

    Article  CAS  PubMed  Google Scholar 

  • de Groot S, Redekop WK, et al. Survival in patients with primary metastatic renal cell carcinoma treated with sunitinib with or without previous cytoreductive nephrectomy: results from a population-based registry. Urology. 2016;95:121–7.

    Article  PubMed  Google Scholar 

  • Guha N, Loomis D, et al. Carcinogenicity of trichloroethylene, tetrachloroethylene, some other chlorinated solvents, and their metabolites. Lancet Oncol. 2012;13(12):1192–3.

    Article  PubMed  Google Scholar 

  • Haas NB, Manola J, et al. Initial results from ASSURE (E2805): adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. ASCO Meet Abstr. 2015;33(7 suppl):403.

    Google Scholar 

  • Han KR, Pantuck AJ, et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003;61(2):314–9.

    Article  PubMed  Google Scholar 

  • Hanna N, Sun M, et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a National Cancer Database study. J Clin Oncol. 2016;34(27):3267–75.

    Article  PubMed  PubMed Central  Google Scholar 

  • Hanzly M, Aboumohamed A, et al. High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience. Urology. 2014;83(5):1129–34.

    Article  PubMed  Google Scholar 

  • Harada Y, Nonomura N, et al. Clinical study of brain metastasis of renal cell carcinoma. Eur Urol. 1999;36(3):230–5.

    Article  CAS  PubMed  Google Scholar 

  • Heng DY, Xie W, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–9.

    Article  CAS  PubMed  Google Scholar 

  • Heng DY, Xie W, et al. External validation and comparison with other models of the International Metastatic Renal Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–8.

    Article  PubMed  PubMed Central  Google Scholar 

  • Heng DY, Choueiri TK, et al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol. 2014a;25(1):149–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Heng DY, Wells JC, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2014b;66(4):704–10.

    Article  PubMed  Google Scholar 

  • Hirano D, Okada Y, et al. Intravesical recurrence after surgical management of urothelial carcinoma of the upper urinary tract. Urol Int. 2012;89(1):71–7.

    Article  PubMed  Google Scholar 

  • Hofmann HS, Neef H, et al. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol. 2005;48(1):77–81. discussion 81–2

    Article  PubMed  Google Scholar 

  • Hudes G, Carducci M, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81.

    Article  CAS  PubMed  Google Scholar 

  • Hunt JD, van der Hel OL, et al. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer. 2005;114(1):101–8.

    Article  CAS  PubMed  Google Scholar 

  • Hunter GK, Balagamwala EH, et al. The efficacy of external beam radiotherapy and stereotactic body radiotherapy for painful spinal metastases from renal cell carcinoma. Pract Radiat Oncol. 2012;2(4):e95–e100.

    Article  PubMed  Google Scholar 

  • Iacovelli R, Lanoy E, et al. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. BJU Int. 2012;110(11):1747–53.

    Article  PubMed  Google Scholar 

  • Ikushima H, Tokuuye K, et al. Fractionated stereotactic radiotherapy of brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2000;48(5):1389–93.

    Article  CAS  PubMed  Google Scholar 

  • Itano NB, Blute ML, et al. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol. 2000;164(2):322–5.

    Article  CAS  PubMed  Google Scholar 

  • Janowitz T, Welsh SJ, et al. Adjuvant therapy in renal cell carcinoma – past, present, and future. Semin Oncol. 2013;40(4):482–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jonasch E, Wood CG, et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(25):4076–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kader AK, Tamboli P, et al. Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience. J Urol. 2007;177(3):855–60. discussion 860–1

    Article  PubMed  Google Scholar 

  • Kane CJ, Mallin K, et al. Renal cell cancer stage migration: analysis of the National Cancer Database. Cancer. 2008;113(1):78–83.

    Article  PubMed  Google Scholar 

  • Kanzaki R, Higashiyama M, et al. Long-term results of surgical resection for pulmonary metastasis from renal cell carcinoma: a 25-year single-institution experience. Eur J Cardiothorac Surg. 2011;39(2):167–72.

    Article  PubMed  Google Scholar 

  • Karakiewicz PI, Briganti A, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol. 2007;25(11):1316–22.

    Article  PubMed  Google Scholar 

  • Kavolius JP, Mastorakos DP, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998;16(6):2261–6.

    Article  CAS  PubMed  Google Scholar 

  • Kawashima A, Nakayama M, et al. Pulmonary metastasectomy in patients with renal cell carcinoma: a single-institution experience. Int J Clin Oncol. 2011;16(6):660–5.

    Article  PubMed  Google Scholar 

  • Kierney PC, van Heerden JA, et al. Surgeon’s role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. Ann Surg Oncol. 1994;1(4):345–52.

    Article  CAS  PubMed  Google Scholar 

  • Kitamura H, Takahashi A, et al. Molecular-targeted therapy and surgery may prolong survival of renal cell carcinoma patients with bone metastasis: a multi-institutional retrospective study in Japan. Anticancer Res. 2016;36(10):5531–6.

    Article  PubMed  Google Scholar 

  • Kletscher BA, Qian J, et al. Prospective analysis of the incidence of ipsilateral adrenal metastasis in localized renal cell carcinoma. J Urol. 1996;155(6):1844–6.

    Article  CAS  PubMed  Google Scholar 

  • Kollender Y, Bickels J, et al. Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention. J Urol. 2000;164(5):1505–8.

    Article  CAS  PubMed  Google Scholar 

  • Kucerova P, Cervinkova M. Spontaneous regression of tumour and the role of microbial infection – possibilities for cancer treatment. Anti-Cancer Drugs. 2016;27(4):269–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kuczyk M, Wegener G, et al. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Eur Urol. 2005;48(2):252–7.

    Article  CAS  PubMed  Google Scholar 

  • Kutikov A, Uzzo RG, et al. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int. 2010;106(2):218–23.

    Article  PubMed  Google Scholar 

  • Kwak C, Park YH, et al. Metastasectomy without systemic therapy in metastatic renal cell carcinoma: comparison with conservative treatment. Urol Int. 2007;79(2):145–51.

    Article  PubMed  Google Scholar 

  • Lara PN Jr, Tangen CM, et al. Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. J Urol. 2009;181(2):512–6. discussion 516–7

    Article  PubMed  Google Scholar 

  • Lee SE, Kwak C, et al. Metastatectomy prior to immunochemotherapy for metastatic renal cell carcinoma. Urol Int. 2006;76(3):256–63.

    Article  PubMed  Google Scholar 

  • Lee JY, Kim CK, et al. Volume doubling time and growth rate of renal cell carcinoma determined by helical CT: a single-institution experience. Eur Radiol. 2008;18(4):731–7.

    Article  PubMed  Google Scholar 

  • Leibovich BC, Blute ML, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97(7):1663–71.

    Article  PubMed  Google Scholar 

  • Li H, Samawi H, et al. The use of prognostic factors in metastatic renal cell carcinoma. Urol Oncol. 2015;33(12):509–16.

    Article  PubMed  Google Scholar 

  • Lokich J. Spontaneous regression of metastatic renal cancer. Case report and literature review. Am J Clin Oncol. 1997;20(4):416–8.

    Article  CAS  PubMed  Google Scholar 

  • Lowrance WT, Ordonez J, et al. CKD and the risk of incident cancer. J Am Soc Nephrol. 2014;25(10):2327–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Majewski W, Tabor M, et al. The efficacy of stereotactic radiotherapy for metastases from renal cell carcinoma. Neoplasma. 2016;63(1):99–106.

    Article  CAS  PubMed  Google Scholar 

  • Margulis V, Matin SF, et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol. 2008;180(1):94–8.

    Article  PubMed  Google Scholar 

  • Margulis V, McDonald M, et al. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. J Urol. 2009;181(5):2044–51.

    Article  PubMed  Google Scholar 

  • Margulis V, Shariat SF, et al. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur Urol. 2013;63(5):947–52.

    Article  CAS  PubMed  Google Scholar 

  • Mathieu R, Pignot G, et al. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. Urol Oncol. 2015;33(8):339.e9–e15.

    Article  Google Scholar 

  • McDermott DF, Regan MM, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23(1):133–41.

    Article  CAS  PubMed  Google Scholar 

  • McKay RR, Kroeger N, et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol. 2014;65(3):577–84.

    Article  PubMed  Google Scholar 

  • Mehta MP, Tsao MN, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys. 2005;63(1):37–46.

    Article  PubMed  Google Scholar 

  • Meimarakis G, Angele M, et al. Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases. Am J Surg. 2011;202(2):158–67.

    Article  PubMed  Google Scholar 

  • Mickisch GH, Garin A, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.

    Article  CAS  PubMed  Google Scholar 

  • Mitchell AP, Hirsch BR, et al. Deferred systemic therapy in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2015;13(3):e159–66.

    Article  PubMed  Google Scholar 

  • Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26(305):234–41.

    Article  CAS  PubMed  Google Scholar 

  • Motzer RJ, Bander NH, et al. Renal-cell carcinoma. N Engl J Med. 1996;335(12):865–75.

    Article  CAS  PubMed  Google Scholar 

  • Motzer RJ, Mazumdar M, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530–40.

    Article  CAS  PubMed  Google Scholar 

  • Motzer RJ, Bacik J, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289–96.

    Article  CAS  PubMed  Google Scholar 

  • Motzer RJ, Hutson TE, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.

    Article  CAS  PubMed  Google Scholar 

  • Motzer RJ, Escudier B, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56.

    Article  CAS  PubMed  Google Scholar 

  • Motzer RJ, Escudier B, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Murthy SC, Kim K, et al. Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann Thorac Surg. 2005;79(3):996–1003.

    Article  PubMed  Google Scholar 

  • Negrier S, Escudier B, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med. 1998;338(18):1272–8.

    Article  CAS  PubMed  Google Scholar 

  • Negrier S, Perol D, et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer. 2007;110(11):2468–77.

    Article  CAS  PubMed  Google Scholar 

  • Nunez Bragayrac L, Hoffmeyer J, et al. Minimally invasive cytoreductive nephrectomy: a multi-institutional experience. World J Urol. 2016;34(12):1651–6.

    Article  PubMed  Google Scholar 

  • Oliver RT, Nethersell AB, et al. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol. 1989;63(2):128–31.

    Article  CAS  PubMed  Google Scholar 

  • Pantuck AJ, Belldegrun AS, et al. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med. 2001;345(23):1711–2.

    Article  CAS  PubMed  Google Scholar 

  • Park SS, Dong H, et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res. 2015;3(6):610–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Patard JJ, Kim HL, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004;22(16):3316–22.

    Article  PubMed  Google Scholar 

  • Petrelli F, Coinu A, et al. Cytoreductive nephrectomy in metastatic renal cell carcinoma treated with targeted therapies: a systematic review with a meta-analysis. Clin Genitourin Cancer. 2016;14(6):465–72.

    Article  PubMed  Google Scholar 

  • Pfannschmidt J, Hoffmann H, et al. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg. 2002;74(5):1653–7.

    Article  PubMed  Google Scholar 

  • Pierorazio PM, McKiernan JM, et al. Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed. BJU Int. 2007;100(4):755–9.

    Article  PubMed  Google Scholar 

  • Piltz S, Meimarakis G, et al. Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg. 2002;73(4):1082–7.

    Article  PubMed  Google Scholar 

  • van der Poel HG, Roukema JA, et al. Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur Urol. 1999;35(3):197–203.

    Article  PubMed  Google Scholar 

  • Procopio G, Verzoni E, et al. Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastases. Tumori. 2014;100(1):e28–30.

    PubMed  Google Scholar 

  • Psutka SP, Kim SP, et al. The impact of targeted therapy on management of metastatic renal cell carcinoma: trends in systemic therapy and cytoreductive nephrectomy utilization. Urology. 2015;85(2):442–50.

    Article  PubMed  Google Scholar 

  • Ranck MC, Golden DW, et al. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol. 2013;36(6):589–95.

    Article  CAS  PubMed  Google Scholar 

  • Ravaud A, Motzer RJ, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375(23):2246–54.

    Article  CAS  PubMed  Google Scholar 

  • Reddy S, Wolfgang CL. The role of surgery in the management of isolated metastases to the pancreas. Lancet Oncol. 2009;10(3):287–93.

    Article  PubMed  Google Scholar 

  • Renehan AG, Tyson M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78.

    Article  PubMed  Google Scholar 

  • Rini BI, Dorff TB, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 2016;17(9):1317–24.

    Article  PubMed  Google Scholar 

  • Robin HI, AuBuchon J, et al. The abscopal effect: demonstration in lymphomatous involvement of kidneys. Med Pediatr Oncol. 1981;9(5):473–6.

    Article  CAS  PubMed  Google Scholar 

  • Robson CJ, Churchill BM, et al. The results of radical nephrectomy for renal cell carcinoma. Trans Am Assoc Genitourin Surg. 1968;60:122–9.

    CAS  PubMed  Google Scholar 

  • Rothermundt C, Hader C, et al. Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer. Ann Oncol. 2016;27(3):544–5.

    Article  CAS  PubMed  Google Scholar 

  • Russo P, Synder M, et al. Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. ScientificWorldJournal. 2007;7:768–78.

    Article  PubMed  Google Scholar 

  • Samlowski WE, Majer M, et al. Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery. Cancer. 2008;113(9):2539–48.

    Article  PubMed  Google Scholar 

  • Sanli O, Zorba OU, et al. Microscopic venous invasion is associated with disease free and cancer free survival in renal cell carcinoma. Minerva Urol Nefrol. 2010;62(4):347–53.

    CAS  PubMed  Google Scholar 

  • Schoggl A, Kitz K, et al. Gamma-knife radiosurgery for brain metastases of renal cell carcinoma: results in 23 patients. Acta Neurochir. 1998;140(6):549–55.

    Article  CAS  PubMed  Google Scholar 

  • Shuch B, La Rochelle JC, et al. Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. Cancer. 2008;113(6):1324–31.

    Article  PubMed  Google Scholar 

  • Siemer S, Lehmann J, et al. Adrenal metastases in 1635 patients with renal cell carcinoma: outcome and indication for adrenalectomy. J Urol. 2004;171(6 Pt 1):2155–9. discussion 9

    Article  CAS  PubMed  Google Scholar 

  • Smaldone MC, Handorf E, et al. Temporal trends and factors associated with systemic therapy after cytoreductive nephrectomy: an analysis of the National Cancer Database. J Urol. 2015;193(4):1108–13.

    Article  PubMed  Google Scholar 

  • Smith EM, Kursh ED, et al. Treatment of osseous metastases secondary to renal cell carcinoma. J Urol. 1992;148(3):784–7.

    Article  CAS  PubMed  Google Scholar 

  • Stewart GD, Aitchison M, et al. Cytoreductive nephrectomy in the tyrosine kinase inhibitor era: a question that may never be answered. Eur Urol. 2016;71(6):845–7.

    Article  PubMed  Google Scholar 

  • Tanguay S, Pisters LL, et al. Therapy of locally recurrent renal cell carcinoma after nephrectomy. J Urol. 1996;155(1):26–9.

    Article  CAS  PubMed  Google Scholar 

  • Tosco L, Van Poppel H, et al. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma. Eur Urol. 2013;63(4):646–52.

    Article  PubMed  Google Scholar 

  • Tsao CK, Small AC, et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World J Urol. 2013;31(6):1535–9.

    Article  PubMed  Google Scholar 

  • Tsui KH, Shvarts O, et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163(4):1090–5. quiz 295

    Article  CAS  PubMed  Google Scholar 

  • Vajdic CM, McDonald SP, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296(23):2823–31.

    Article  CAS  PubMed  Google Scholar 

  • Wagner JR, Walther MM, et al. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol. 1999;162(1):43–5.

    Article  CAS  PubMed  Google Scholar 

  • Walther MM, Alexander RB, et al. Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology. 1993;42(3):250–7. discussion 257–8

    Article  CAS  PubMed  Google Scholar 

  • Walther MM, Yang JC, et al. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol. 1997;158(5):1675–8.

    Article  CAS  PubMed  Google Scholar 

  • Wersall PJ, Blomgren H, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol. 2005;77(1):88–95.

    Article  PubMed  Google Scholar 

  • Wersall PJ, Blomgren H, et al. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol. 2006;45(4):493–7.

    Article  PubMed  Google Scholar 

  • Williams AK, Kassouf W, et al. Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma. Urol Oncol. 2013;31(7):1161–5.

    Article  PubMed  Google Scholar 

  • Winter JM, Cameron JL, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10(9):1199–210. discussion 210–1

    Article  PubMed  Google Scholar 

  • Wronski M, Maor MH, et al. External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys. 1997;37(4):753–9.

    Article  CAS  PubMed  Google Scholar 

  • Yagoda A, Petrylak D, et al. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am. 1993;20(2):303–21.

    CAS  PubMed  Google Scholar 

  • Yang JC, Sherry RM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21(16):3127–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • You D, Jeong IG, et al. The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. J Urol. 2011;185(1):54–9.

    Article  PubMed  Google Scholar 

  • Zelefsky MJ, Greco C, et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2012;82(5):1744–8.

    Article  PubMed  Google Scholar 

  • Zhang S. Adjuvant sunitinib in renal-cell carcinoma. N Engl J Med. 2017;376(9):893.

    Article  PubMed  Google Scholar 

  • Zisman A, Pantuck AJ, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19(6):1649–57.

    Article  CAS  PubMed  Google Scholar 

  • Znaor A, Lortet-Tieulent J, et al. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519–30.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, USA

    Laura-Maria Krabbe, Solomon L. Woldu, Oner Sanli & Vitaly Margulis

  2. Department of Urology, University of Muenster Medical Center, Muenster, Germany

    Laura-Maria Krabbe

Authors
  1. Laura-Maria Krabbe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Solomon L. Woldu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Oner Sanli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vitaly Margulis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laura-Maria Krabbe .

Editor information

Editors and Affiliations

  1. Dept. of Urology & Urologic Oncology, Hannover Medical School, Hannover, Germany

    Axel S. Merseburger

  2. Dept. of Urology, University of Regensburg St. Josef Medical Centre, Regensburg, Germany

    Maximilian Burger

Section Editor information

  1. Klinik für Urologie, Ratzeburger Allee 160, 23538, Lübeck, Germany

    Mario W. Kramer

  2. Department of Urology, University Hospital Schleswig-Holstein, Ratzeburger Allee 160, 23538, Lübeck, Germany

    Axel S. Merseburger

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this entry

Cite this entry

Krabbe, LM., Woldu, S.L., Sanli, O., Margulis, V. (2017). Metastatic Surgery in Advanced Renal Cell Carcinoma. In: Merseburger, A., Burger, M. (eds) Urologic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-42603-7_65-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42603-7_65-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42603-7

  • Online ISBN: 978-3-319-42603-7

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation